Immunitybio Inc
Statements
Cash Flow
Immunitybio Inc (IBRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -142 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11 | -11 | -10 | -15 | -10 | -14 | -16 | -16 | -18 | -14 | -13 | -17 | -17 | -15 | -31 | -46 | -37 | -58 | -60 | -70 | -73 | -72 | -75 | -91 | -81 | -91 | -84 | -80 | -87 | -115 | -107 | -100 | -99 | -85 | -86 | -80 | -69 | -70 | -75 | -142 | -356 | |
| 0.8 | 1.8 | 1.2 | 1.4 | 1.5 | 1.6 | 1.6 | 2.4 | 2.8 | 2.8 | 3.0 | 1.6 | 2.2 | 2.2 | 3.5 | 3.5 | 3.6 | 2.2 | 3.0 | 4.0 | 3.7 | 3.7 | 4.5 | 4.8 | 9.0 | 5.2 | 4.7 | 4.7 | 16 | 4.6 | 4.6 | 4.4 | 4.4 | 4.1 | 3.8 | 3.9 | 4.0 | 3.9 | 4.4 | 8.8 | 21 | |
| 19 | 11 | 10 | 9.4 | 8.7 | 8.9 | 9.1 | 8.9 | 4.0 | 1.4 | 1.4 | 0.5 | 0.3 | 0.1 | 0.5 | 0.3 | 0.7 | 0.7 | 15 | 18 | 14 | 10 | 10 | 10 | 11 | 9.4 | 11 | 11 | 14 | 13 | 8.3 | 9.6 | 7.5 | 9.0 | 9.5 | 9.6 | 8.9 | 8.7 | 8.2 | 17 | 42 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1.0 | 2.4 | 1.6 | – | -2.4 | 11 | 21 | 14 | 11 | 11 | 21 | 7.1 | -2.4 | -17 | 33 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -3.7 | -12 | -11 | -37 | -17 | -17 | -4.2 | -18 | -20 | -8.7 | 24 | -11 | -16 | -2.7 | 0.1 | -3.6 | 7.9 | 7.8 | -1.0 | -2.0 | -12 | -3.2 | 8.8 | -24 | 6.4 | -6.6 | 28 | 9.1 | -4.3 | -26 | -3.9 | 5.4 | -10 | -11 | -22 | -5.6 | -12 | -14 | -0.5 | -0.9 | -28 | |
| 3.1 | 1.4 | 4.5 | 8.2 | 11 | 11 | 4.9 | 2.5 | 3.7 | 2.0 | 2.1 | 1.0 | 0.4 | 0.7 | 0.3 | 0.0 | 2.0 | 0.7 | 7.1 | 8.0 | 8.0 | 10 | 27 | 16 | 16 | 19 | 8.4 | 8.5 | 5.7 | 8.0 | 1.3 | 0.7 | 2.8 | 2.1 | 1.1 | 1.1 | 0.8 | 1.3 | 1.8 | 5.3 | 9.1 | |
| 6.9 | -8.5 | 16 | 57 | 7.0 | 20 | 2.9 | 21 | 17 | 16 | -19 | 11 | 17 | 12 | 14 | 15 | -57 | 7.5 | 32 | 10 | 11 | -138 | -69 | 117 | -1.2 | -19 | -8.5 | -8.6 | -16 | 2.2 | -36 | -51 | 65 | 9.8 | 4.1 | -16 | -181 | 44 | -32 | -139 | -309 | |
| – | 1.4 | – | – | – | 1.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.2 | 0.4 | 0.1 | 1.5 | – | 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | |
| -2.6 | -3.9 | -1.1 | -11 | – | -2.8 | -2.8 | – | – | -0.2 | -0.2 | – | – | – | -0.1 | 0.0 | -0.5 | 0.0 | -2.6 | 98 | 44 | -0.5 | -0.4 | 0.0 | 0.0 | -0.2 | -0.4 | -0.1 | -1.5 | -1.6 | -3.9 | -3.9 | 3.9 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 62 | -3.7 | -3.7 | – | -3.7 | 40 | 299 | 299 | 299 | 124 | 124 | 124 | 50 | 30 | 30 | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.9 | 0.0 | 0.0 | 2.9 | |
| -3.0 | -4.1 | -0.5 | -16 | -15 | -3.1 | -0.1 | -0.2 | -0.1 | -0.4 | 39 | -0.5 | 0.0 | -0.1 | -0.1 | 87 | 63 | 0.2 | 38 | 98 | 43 | 326 | -0.3 | 0.0 | 124 | 110 | 77 | 43 | 238 | 201 | 10 | 149 | 16 | 107 | -1.0 | 173 | 174 | 55 | 224 | 268 | 721 | |
| -6.8 | -23 | 5.5 | 25 | -18 | 3.0 | -13 | 4.9 | -0.8 | 1.5 | 6.7 | -6.0 | 0.8 | -2.8 | -17 | 57 | -30 | -50 | 9.8 | 39 | -19 | 117 | -145 | 26 | 42 | 0.5 | -16 | -45 | 134 | 87 | -132 | -2.9 | -18 | 32 | -83 | 77 | -77 | 28 | 117 | -12 | 56 | |
| -14 | -12 | -15 | -23 | -21 | -25 | -20 | -19 | -21 | -16 | -15 | -18 | -17 | -16 | -31 | -46 | -39 | -57 | -68 | -78 | -81 | -82 | -102 | -107 | -97 | -110 | -93 | -88 | -93 | -123 | -108 | -101 | -102 | -87 | -87 | -81 | -70 | -72 | -77 | -147 | -366 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.